Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
For many years, antimuscarinics have been first-line pharmacological treatment for OAB. A
recent meta-analysis of randomised, controlled trials on antimuscarinic treatment of OAB
concluded that the drugs provide significant improvements in OAB symptoms compared with
placebo but that the benefits are of limited clinical significance. The analysis questioned
the clinical significance of the trial results, one reason for which was the lack of data on
the use of sensitive patient-driven criteria. Traditional symptomatic and urodynamic measures
of treatment success may be meaningful to clinicians but often have little meaning to
patients. Therefore, patient-reported outcomes (PROs), which provide a subjective measure of
a patient's response to treatment, are useful. Recently, clinicians treating OAB have begun
to recognize the value of PROs but still overlook the treatment efficacy in terms of
patient-reported goal achievement (PGA).
Patients with OAB have combination of symptoms and the extent to which individual OAB
symptoms affect patients varies. Also each patient can have different goal for the treatment.
Therefore, assessing the degree of goal achievement in each patient can provide a new aspect
of treatment benefit.
This controlled study will advance the understanding of OAB in terms of patient-centered
treatments goals and goal achievement and will provide a new aspect of treatment benefit.